Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Vicki L. Gordon"'
Autor:
Kallesh D. Jayappa, Brian Tran, Vicki L. Gordon, Christopher Morris, Shekhar Saha, Caroline C. Farrington, Caitlin M. O’Connor, Kaitlin P. Zawacki, Krista M. Isaac, Mark Kester, Timothy P. Bender, Michael E. Williams, Craig A. Portell, Michael J. Weber, Goutham Narla
Publikováno v:
The Journal of Clinical Investigation, Vol 133, Iss 13 (2023)
Targeted therapies such as venetoclax (VEN) (Bcl-2 inhibitor) have revolutionized the treatment of chronic lymphocytic leukemia (CLL). We previously reported that persister CLL cells in treated patients overexpress multiple antiapoptotic proteins and
Externí odkaz:
https://doaj.org/article/533a790882534037b799d173898330eb
Autor:
Kallesh D. Jayappa, Craig A. Portell, Vicki L. Gordon, Brian J. Capaldo, Stefan Bekiranov, Mark J. Axelrod, L. Kyle Brett, Julia D. Wulfkuhle, Rosa I. Gallagher, Emanuel F. Petricoin, Timothy P. Bender, Michael E. Williams, Michael J. Weber
Publikováno v:
Blood Advances, Vol 1, Iss 14, Pp 933-946 (2017)
Abstract: De novo resistance and rapid recurrence often characterize responses of B-cell malignancies to ibrutinib (IBR), indicating a need to develop drug combinations that block compensatory survival signaling and give deeper, more durable response
Externí odkaz:
https://doaj.org/article/8971b2c6746d4ca78045d1f18e8e94de
Autor:
B. Dharmaveer Shetty, Konrad J. Cios, Kallesh Danappa Jayappa, Vicki L. Gordon, Craig A. Portell, Michael J. Weber, Briana Wilson, Krista Isaac, Michael E. Williams, Puja C. Arora, Timothy P. Bender, Christopher Morris, Shekhar Saha
Publikováno v:
Blood Adv
The Bcl-2 inhibitor venetoclax has yielded exceptional clinical responses in chronic lymphocytic leukemia (CLL). However, de novo resistance can result in failure to achieve negative minimal residual disease and predicts poor treatment outcomes. Cons
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e28ee8bb65f7c14c815b1b62db27780a
https://doi.org/10.1182/bloodadvances.2020003944
https://doi.org/10.1182/bloodadvances.2020003944
Autor:
Goutham Narla, Shekhar Saha, Timothy P. Bender, Christopher Morris, Krista Isaac, Caroline Farrington, Kallesh Danappa Jayappa, Michael J. Weber, Vicki L. Gordon, Craig A. Portell, Michael E. Williams
Publikováno v:
Blood. 136:15-17
The advent of molecularly targeted therapies has revolutionized the treatment of Non-Hodgkin's Lymphoma (NHL), including Chronic Lymphocytic Leukemia (CLL). Venetoclax (VEN, an inhibitor of Bcl-2) and ibrutinib (IBR, an inhibitor of BTK) generated ex
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a91c96e86103319e2537f778673cb843
https://doi.org/10.1182/blood-2020-138954
https://doi.org/10.1182/blood-2020-138954
Autor:
Shekhar Saha, Michael E. Williams, Michael J. Weber, Craig A. Portell, Goutham Narla, Krista Isaac, Caroline Farrington, Christopher Morris, Timothy P. Bender, Vicki L. Gordon, Kallesh Danappa Jayappa
Publikováno v:
Cancer Research. 81:937-937
The Bcl-2 inhibitor venetoclax (VEN) shows clinical activity in Chronic Lymphocytic Leukemia (CLL), and the response is potentiated when combined with the BTK inhibitor ibrutinib (IBR) (Portell et al. 2019; Tam et al. 2018). However, many VEN or VEN+
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::33006b5abf046b1dfbd790faf990a8c0
https://doi.org/10.1158/1538-7445.am2021-937
https://doi.org/10.1158/1538-7445.am2021-937
Autor:
Stefan Bekiranov, Timothy P. Bender, Julia Wulfkuhle, Emanuel F. Petricoin, Michael J. Weber, Mark J. Axelrod, Vicki L. Gordon, Kallesh Danappa Jayappa, Michael E. Williams, Rosa I. Gallagher, Brian J. Capaldo, L. Kyle Brett, Craig A. Portell
Publikováno v:
Blood Advances. 1:933-946
De novo resistance and rapid recurrence often characterize responses of B-cell malignancies to ibrutinib (IBR), indicating a need to develop drug combinations that block compensatory survival signaling and give deeper, more durable responses. To iden
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::64866bdcef5a8fba29eec7d795e30ebc
https://doi.org/10.1182/bloodadvances.2016004176
https://doi.org/10.1182/bloodadvances.2016004176
Autor:
Kallesh D. Jayappa, Vicki L. Gordon, Konrad J. Cios, Christopher G. Morris, Puja C. Arora, Timothy P. Bender, Michael E. Williams, Craig A. Portell, Michael J. Weber
Publikováno v:
Cancer Research. 79:3031-3031
Responses to ibrutinib (IBR) or venetoclax (VEN) in Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL) are often partial. We reported synergistic toxicity for the IBR+VEN combination in CLL/MCL ex vivo and initiated an IBR+VEN trial in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::300d2821ef9a535c8dd13c16fd82fa7f
https://doi.org/10.1158/1538-7445.am2019-3031
https://doi.org/10.1158/1538-7445.am2019-3031
Autor:
Elyse Lopez, M L Wang, Richard J. Ford, Archito T. Tamayo, Mark J. Axelrod, Michael J. Weber, Laura Kyle Brett, Liang Zhang, Vicki L. Gordon, Michael E. Williams, Zhishuo Ou, L V Pham
Publikováno v:
Leukemia
Combinatorial drug screening identifies synergistic co-targeting of Bruton’s tyrosine kinase and the proteasome in mantle cell lymphoma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7680f05c49170c83a43983b5e4a1135f
https://doi.org/10.1038/leu.2013.249
https://doi.org/10.1038/leu.2013.249
Autor:
Michael E. Williams, Michael J. Weber, Vicki L. Gordon, Timothy P. Bender, Kallesh Danappa Jayappa, Craig A. Portell, Goutham Narla
Publikováno v:
Blood. 132:2649-2649
Ibrutinib (IBR), an inhibitor of Bruton's Tyrosine Kinase (Btk) and venetoclax (VEN), an inhibitor of Bcl-2 have been used in Chronic Lymphocytic Leukemia (CLL), but single agent responses to these drugs are often incomplete and not durable. We previ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9919bb4bfd39ac53101313f2ecf66dc8
https://doi.org/10.1182/blood-2018-99-116759
https://doi.org/10.1182/blood-2018-99-116759
Autor:
Konrad J. Cios, Michael J. Weber, Vicki L. Gordon, Puja C. Arora, Timothy P. Bender, Michael E. Williams, Craig A. Portell, Kallesh Danappa Jayappa
Publikováno v:
Blood. 132:4120-4120
Responses to single-agent ibrutinib (IBR) or venetoclax (VEN) in Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL) are often incomplete suggesting drug combinations are needed to overcome de novo and acquired resistance. We previously
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7d58d8f8df22c68a740ca467b4896705
https://doi.org/10.1182/blood-2018-99-119521
https://doi.org/10.1182/blood-2018-99-119521